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Abstract 21 
Antibiotics typically fail to completely eradicate a bacterial population, leaving a small fraction 22 
of transiently antibiotic-tolerant persister cells intact. Persisters are therefore seen as a major 23 
cause of treatment failure and greatly contribute to the recalcitrant nature of chronic infections. 24 
The current report is focused on Pseudomonas aeruginosa, a Gram-negative pathogen 25 
belonging to the notorious ESKAPE group and, due to an increasing resistance against most 26 
conventional antibiotics, posing a serious threat to human health. Greatly contributing to the 27 
difficult treatment of P. aeruginosa infections is the presence of persister cells and elimination 28 
of these cells would therefore significantly improve patient outcome. In this study, a small-29 
molecule library was screened for compounds that, in combination with the fluoroquinolone 30 
antibiotic ofloxacin, reduced the number of P. aeruginosa persisters as compared to treatment 31 
with the antibiotic alone. Based on early structure-activity relationship, 1-((2,4-32 
dichlorophenethyl)amino)-3-phenoxypropan-2-ol (SPI009) was selected for further 33 
characterization. Combination of SPI009 with mechanistically distinct classes of antibiotics 34 
reduced the number of persisters up to 106-fold in both lab strains and clinical isolates of P. 35 
aeruginosa. Further characterization of the compound revealed a direct and efficient killing of 36 
persister cells. SPI009 caused no erythrocyte damage and demonstrated minor cytotoxicity. In 37 
conclusion, we identified a novel anti-persister compound active against P. aeruginosa with 38 
promising applications for the design of novel, case-specific combination therapies in the fight 39 
against chronic infections. 40 
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Introduction 41 
Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen best known as the 42 
dominant cause of life-threatening chronic airway infections in cystic fibrosis (CF) patients (1). 43 
Infections are also commonly found in highly vulnerable patients such as burn wound victims, 44 
immunocompromised individuals and patients residing in intensive care units (2, 3). In addition 45 
to an intrinsic resistance towards a wide variety of antibiotics, P. aeruginosa has the remarkable 46 
ability to acquire additional resistance mechanisms. Rapidly increasing resistance to multiple 47 
antibiotic classes, including the so-called last-resort polymyxins, classifies the pathogen as 48 
multidrug- or even pan-resistant and have caused P. aeruginosa infections to become 49 
increasingly difficult to treat (2, 4, 5). P. aeruginosa is 4th most common cause of healthcare-50 
associated infections in Europe (8.9%) with 14% of all isolates reported as being resistant to at 51 
least three antimicrobial classes (6, 7). The World Health Organization (WHO) has recently 52 
ranked P. aeruginosa as ‘critical’ in the ‘Global priority list of antibiotic-resistant bacteria to 53 
guide research, discovery and development of new antibiotics’, emphasizing its clear clinical 54 
importance and encouraging the development of novel antibacterial therapies (8, 9).  55 
Some infections however, prove difficult to eradicate despite the absence of clinically 56 
detectable resistance against the used antibiotic (10). This can be explained by the presence of 57 
persister cells, a small fraction of phenotypical variants in a genetically homogeneous 58 
population that is tolerant to treatment with high doses of antibiotics (11, 12). It is generally 59 
assumed that, upon successful treatment with a bactericidal antibiotic, the host immune system 60 
is able to cope with this small fraction of surviving cells. However, in situations where the 61 
immune system is compromised or bacteria are able to evade the immune system, persisters 62 
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become a threat to human health and are considered a major culprit in chronic infections (13). 63 
Persister cells greatly contribute to the observed antibiotic tolerance in biofilms, are responsible 64 
for the recalcitrant nature of chronic infections (10, 14, 15) and recently, evidence is gathering 65 
that persister cells can facilitate the emergence of genetic resistance (16–19). Targeting 66 
persisters is therefore likely to greatly improve patient outcomes in chronic infectious diseases. 67 
Despite the clear clinical relevance of persisters, there are still few anti-persister compounds 68 
described in literature (20). Contributing to this is the still limited knowledge on the 69 
mechanisms behind persister formation in P. aeruginosa, the fact that multiple, redundant 70 
pathways seem to be involved and the observation that the processes implicated in persistence 71 
seem to be species-specific (21, 22). Therefore, the rational design of target-based anti-persister 72 
therapies remains difficult. 73 
Here, we describe the screening of a diverse set of small-molecule compounds that resulted in 74 
the identification of the potent anti-persister compound SPI009. This molecule strongly reduces 75 
or even completely eradicates persisters of P. aeruginosa when administered in combination 76 
with mechanistically distinct antibiotics. Importantly, SPI009 retains its activity against several 77 
clinical isolates, directly kills persister cells in a highly efficient manner and causes no hemolytic 78 
effects.  79 
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Materials and methods 80 
Bacterial strains, human cell lines and culture conditions. Bacterial strains were cultured in 81 
1:20 diluted Trypticase Soy Broth (1:20 TSB) at 37 °C, shaking at 200 rpm. For solid medium, TSB 82 
was supplemented with 1.5% agar. Human HEK293-T cells were cultivated in DMEM medium 83 
containing 5% heat-inactivated FCS and kept at 37°C with 5% CO2. The following antibiotics were 84 
used: ofloxacin, ceftazidime (Sigma Aldrich) and amikacin (Acros). Concentrations are indicated 85 
throughout the text. The small-molecule library was provided by the Centre for Drug Design and 86 
Discovery (CD3) of the KU Leuven (23, 24). Bacterial strains used in this study are listed in Table 87 
1.  88 
Anti-persister screening assay. The small-molecule library was screened for anti-persister 89 
activity as previously described (25). Briefly, stationary phase cells of P. aeruginosa cultured in 90 
1:20 TSB were treated for 5 hours with a combination of ofloxacin (10 µg/mL) and test 91 
compound (10 µg/mL, corresponding to 20-50 µM of compound). Treated cells were diluted 92 
100-fold into fresh TSB growth medium and incubated in an automated OD plate reader 93 
(Bioscreen C, Oy Growth Curves Ab Ltd.) at 37°C with aeration. Previous research revealed a 94 
linear relationship between the number of cells incubated in the automated plate reader and 95 
the time it took to reach an OD600 of 0.6 with y(OD)=-2.1574x(t) + 28.792 and R
2=0.987 (26). 96 
Based on this relationship, 105 compounds were selected that showed delayed growth and thus 97 
decreased the number of surviving persister cells. Of the 15 most interesting compounds, 98 
showing a significant reduction in persister fraction, 5 compounds, belonging to three 99 
structurally distinct families, were further confirmed via plate counting. Family 1 proved most 100 
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active and 19 chemical analogues of compound SPI001 were subjected to a structure-activity 101 
relationship study (Table 2). 102 
MIC assay. Minimal Inhibitory Concentrations (MIC’s) were determined using the EUCAST 103 
standards for broth microdilution (27). The starting inoculum was adapted to approximately 5 x 104 
105 cells/mL and incubated in the presence of a 2-fold dilution series of SPI009 for 24 hours, 105 
shaking at 37°C. MIC was determined as the lowest concentration completely inhibiting 106 
bacterial growth. 107 
Treatment of isolated persister cells. Persister cells were isolated as described previously, with 108 
minor modifications (28). Stationary phase cells were treated for 5 hours with ofloxacin (10 109 
µg/mL). Higher ofloxacin concentrations or increased incubation times did not lead to a further 110 
reduction of the number of surviving cells (data not shown). Persisters were washed twice with 111 
0.85% NaCl (5200 x g, 15 minutes, 4 °C) and subsequently used for killing assays, as described 112 
below. 113 
Killing assays. Killing assays were performed as previously described (29). Briefly, stationary 114 
phase cultures were treated with a combination of antibiotic and compound (anti-persister 115 
effect) or compound alone (bactericidal effect). Antibiotic concentrations were chosen to allow 116 
only persister cells to survive, indicated by a drop in killing rate. 200 µL volumes of treated 117 
culture were dispensed in a 96-well plate and incubated for 5 hours at 37 °C, shaking at 200 118 
rpm. To explore the effect of different treatment regimens, SPI009 was added 0; 5 or 24 hours 119 
after the onset of ofloxacin treatment and cells were treated for a total of 72 hours. For time-kill 120 
curves different treatment durations were chosen between 15 minutes and 24 hours, 121 
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comprising treatment with DMSO (0.5%; solvent control), ofloxacin (10 µg/mL), SPI009 alone 122 
(17 or 34 µg/mL) and the combination of ofloxacin with SPI009. To assess the effect of different 123 
classes of antibiotics stationary phase or exponential phase cultures were treated with 75 124 
µg/mL amikacin or 30 µg/mL ceftazidime for 5 hours. After treatment, cells were washed twice 125 
in 10 mM MgSO4 (3300 x g, 10 minutes, 4 °C) after which appropriate dilutions were plated on 126 
solid growth medium to determine the number of viable cells. Plates were monitored for 72 127 
hours to ensure detection of slow growing colonies. 128 
Cytotoxicity assay. Cytotoxicity was evaluated through colorimetric determination of the lactate 129 
dehydrogenase (LDH) activity released from the cytosol of damaged cells (Cytotoxicity Detection 130 
Kit PLUS). HEK293-T cells were seeded at concentrations of 1.25 x 104 cells/well in 50 µL of 131 
appropriate medium and adhesion was allowed overnight. The eukaryotic cells were exposed to 132 
increasing concentrations of SPI009 for 24 hours, after which LDH activity was measured 133 
according to the manufacturer’s guidelines. The relative cytotoxicity was determined as follows:  134 
𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 (%) =  
(𝑆𝑎𝑚𝑝𝑙𝑒 𝑣𝑎𝑙𝑢𝑒 − 𝑙𝑜𝑤 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
(𝐻𝑖𝑔ℎ 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑙𝑜𝑤 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
 𝑥 100 
 135 
Hemolytic assay. Hemolytic activity was assessed as described previously (30), with minor 136 
modifications. Defibrinated whole blood from horses (Oxoid) was washed three times with 137 
10mM Tris-HCl 0.9% NaCl pH 7.4 (1000 x g, 10 minutes, 4°C) with sequential removing of the 138 
buffy coat. Washed erythrocytes were diluted to a final concentration of 2% in 10mM Tris-HCl 139 
0.9% HCl pH 7.4 and pre-incubated in 1 mL volumes for 10 minutes (37 °C). 190 µL of 140 
erythrocytes were mixed with 10 µL of the different testing agents and incubated at 37°C for 1 141 
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hour. 10mM Tris-HCl 0.9% HCl pH 7.4 and 0.1% Triton X-100 were used as negative and positive 142 
controls, respectively. Testing concentrations of SPI009 ranged from 8.5 to 34 µg/mL. After 143 
incubation the erythrocyte solutions were centrifuged for 5 minutes (3000 x g) and absorbance 144 
of the supernatant was measured at 540 nm (Biotek multimode reader) to assess hemolytic 145 
damage. Background controls were subtracted from the OD540 values and % hemolysis 146 
determined relative to the positive control (0.1% Triton X-100). Statistical analysis was 147 
performed on control-corrected OD540 values using unpaired, one-way ANOVA testing with 148 
appropriate correction for multiple comparison (Dunnett) (significance level, α = 0.05). 149 
Statistical analysis. Unless mentioned otherwise, all statistical calculations were performed on 150 
log10-transformed data using GraphPad Prism software (version 6.01). The effect of different 151 
treatments on CFUs was analyzed using unpaired, one-way ANOVA testing, with appropriate 152 
correction for multiple comparison (Dunnett) (significance level, α = 0.05). Averages are the 153 
result of at least three independent repeats. 154 
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Results 155 
Identification and structure-activity relationship of anti-persister compound SPI009 156 
A small-molecule library comprising 23 909 diverse molecules (23) was screened to identify 157 
compounds that reduce the persister fraction of P. aeruginosa in combination with the 158 
fluoroquinolone antibiotic ofloxacin (10 µg/mL). To confirm anti-persister activity of the 159 
identified compounds, a range of concentrations (0-200 µM) was tested and the efficacy was 160 
assessed through viable cell counting. From this analysis, SPI001 was selected for further 161 
characterization. To explore the effect of chemical modifications of the molecule on the 162 
observed activity, commercially available chemical analogues were purchased and evaluated for 163 
their anti-persister effect (Table 2). Based on preliminary experiments (data not shown), the 164 
evaluation of the analogues was carried out using a single concentration of 200 µM, 165 
corresponding to 68 µg/mL, in combination with 10 µg/mL of ofloxacin. Amongst the analogues 166 
that significantly reduced the persister fraction, only SPI009, SPI015 and SPI016 showed an 167 
increase in anti-persister activity compared to the original hit SPI001. SPI009, 1-((2,4-168 
dichlorophenethyl)amino)-3-phenoxypropan-2-ol, had the most pronounced effect, reducing 169 
the persister fraction ~7 200-fold (P < 0.0001) compared to the treatment with ofloxacin alone. 170 
From a structure-activity relationship (SAR) point of view, it is worth noticing that the 7 most 171 
active compounds (fold decrease > 39) are all secondary amines (R3 = hydrogen) whereas most 172 
of the other compounds are tertiary amines (except SPI011, SPI014 and SPI020). Moreover, the 173 
hydroxyl residue (R2) does not seem to be essential for good biological activity (see SPI015), 174 
although this should be confirmed by the evaluation of additional analogues. Finally, it is striking 175 
that the most active analogue (SPI009) is the only compound bearing a phenethyl residue on R4 176 
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instead of a benzyl residue, indicating that there is flexibility in the chain length. Based on all 177 
these results, SPI009 was selected for further characterization. The antibacterial activity of 178 
SPI009 was also evaluated by determination of the MIC value. The MIC value, defined as the 179 
minimal concentration to completely inhibit bacterial growth, as calculated for P. aeruginosa in 180 
1:20 TSB was 150 µM (corresponding to approximately 51 µg/mL).  181 
 182 
SPI009 directly kills isolated persister cells  183 
To investigate whether SPI009 needs to be administered simultaneously with ofloxacin for 184 
maximal activity, the compound was added at different time-points during ofloxacin treatment. 185 
For this, P. aeruginosa stationary phase cells were first treated with ofloxacin (10 µg/mL) and 186 
SPI009 was subsequently added after 0, 5 and 24 hours (Figures 1 a-c). For each experiment, 187 
complete eradication of the bacterial population was achieved within 24 hours after adding 188 
SPI009. These results indicate that SPI009 can be administrated at any point during treatment 189 
without affecting its activity, thus broadening treatment options. 190 
Based on these results, we conclude that SPI009 may act in two different ways. Either SPI009 191 
wakes up persister cells, hereby rendering them sensitive to the bactericidal action of ofloxacin, 192 
or SPI009 kills the persister cells directly. Examples of both strategies have been reported in 193 
literature (31–34). To discriminate between these two possibilities, persister cells were isolated  194 
 and treated with either 10 µg/mL ofloxacin, 17 to 68 µg/mL SPI009 or a combination of 195 
ofloxacin and SPI009 (Figure 2). As expected, treatment of the isolated persisters with ofloxacin 196 
alone only caused a minor decrease in the number of surviving cells, indicating the effective 197 
isolation of persister cells. In contrast, treatment of isolated persister cells with SPI009 caused a 198 
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significant decrease in the number of surviving cells ranging between 0.71 ± 0.24 log and 199 
complete eradication, as compared to ofloxacin treatment. Combination treatment of SPI009 200 
with ofloxacin was able to completely eliminate all bacterial cells at 34 µg/mL (Figure 2). These 201 
results show that SPI009 is capable of directly killing persister cells, even in the absence of 202 
antibiotics. 203 
 204 
SPI009 is capable of killing both normal and persister cells of P. aeruginosa 205 
Previous experiments have clearly shown that SPI009 efficiently targets persister cells. To gain 206 
more information about the bactericidal effect on ‘normal’, non-persister cells, stationary phase 207 
cultures were treated with 10 µg/mL ofloxacin or 17 to 68 µg/mL of SPI009. As expected, 208 
treatment with 10 µg/mL of ofloxacin causes a significant decrease in the number of surviving 209 
cells and allows only persister cells to survive. Treatment of the culture with 34 or 68 µg/mL of 210 
SPI009 alone also significantly decreased the number of surviving cells as compared to the 211 
control, with reductions of 3.22 ± 0.38 and 6.36 ± 0.39 log units, respectively (Figure 3). Since 212 
these decreases are larger than the expected persister fraction, the obtained results clearly 213 
show that SPI009 is capable of killing both persister and normal cells.  214 
 215 
Killing kinetics of SPI009 as mono- and co-therapy 216 
To assess the killing kinetics of SPI009, stationary phase cultures were exposed to different 217 
treatments for 15 minutes to 24 hours. In order to evaluate both the antibacterial and the anti-218 
persister effect of the compound, cells were treated with SPI009 alone (17-34 µg/mL) or with 219 
the combination of SPI009 and ofloxacin (10 µg/mL), respectively. The obtained time-kill curves 220 
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show a slight biphasic pattern where most killing is obtained in the first 3 to 4 hours (Figure 4). 221 
When comparing treatments, the combination treatment of ofloxacin and SPI009 always 222 
outcompetes the monotherapies. The combination of ofloxacin with 17 or 34 µg/mL completely 223 
eradicates the culture after 24 hours or 5 hours of treatment, respectively. In comparison, 5 224 
hour treatment with 10 µg/mL ofloxacin or 100 µM SPI009 alone causes a 2.87 ± 0.35 log and 225 
4.14 ± 0.35 log decrease in the number of surviving cells, respectively. As suspected, use of 226 
SPI009 alone also has an effect on the bacterial culture, causing a maximal 2.36 ± 0.38 and 4.38 227 
± 0.42 log decrease after 3 hours of treatment with 17 or 34 µg/mL, respectively. The effect of 228 
SPI009 is comparable to that of ofloxacin, with a minor increase in bacterial CFUs after 3 hours 229 
for SPI009. 230 
 231 
Activity of SPI009 is antibiotic-independent  232 
In addition to ofloxacin, other antibiotics used to treat P. aeruginosa infections in the clinic 233 
include the aminoglycoside amikacin and the cephalosporin ceftazidime (35). As shown in Figure 234 
5a, 5 hour treatment of SPI009 in combination with 75 µg/ml amikacin completely eradicates 235 
the stationary phase culture while combination with ofloxacin results in significant 3.36 ± 0.45 236 
and 5.58 ± 0.45 log decreases. The combination treatment of ceftazidime with 34 µg/mL SPI009 237 
also significantly reduced the persister fraction (> 3500 fold) in an exponentially growing culture 238 
(Figure 5b). These results clearly show that SPI009 can be combined with different classes of 239 
antibiotics and thus possesses antibiotic-independent activity.  240 
 241 
SPI009 shows potent activity against several clinical isolates 242 
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To test whether SPI009 is also active on other clinically relevant strains, we selected five P. 243 
aeruginosa strains to obtain a panel of isolates originating from different human sources, such 244 
as burn wounds, urine, throat and bronchus, and with different resistance patterns. Being one 245 
of the most dominant bacterial species in CF lungs, several P. aeruginosa isolates from the 246 
sputum or bronchus of CF patients were included in the panel. Ofloxacin concentrations were 247 
optimized for each strain (data not shown). Stationary phase cells of the different cultures were 248 
treated with 10 or 100 µg/mL ofloxacin and the combination of ofloxacin with 17 or 34 µg/mL of 249 
SPI009. Six out of the eight isolates proved extremely susceptible to killing by the combination 250 
treatment, resulting in a (near) complete eradication of the bacterial population (Figure 6). For 251 
the least sensitive strains AA249, resistant against aztreonam, ciprofloxacin, ceftazidime, 252 
imipenem and meropenem, the combination of ofloxacin with 17 or 34 µg/mL SPI009 still 253 
resulted in a significant 2.06 ± 0.55 and 4.69 ± 0.55 log reduction in the number of surviving 254 
cells, respectively. Evaluation of CF derived isolates shows modest sensitivity for ofloxacin and 255 
demonstrates the potent activity of SPI009 resulting in 4.1 ± 0.3, 4.8 ± 0.3 and 3.7 ± 0.5 log units 256 
decrease in surviving cells when treated with the combination of ofloxacin and 34 µg/mL SPI009 257 
for DAF87-203, PA1256 and PA1255, respectively. In summary, SPI009 shows potent anti-258 
persister activity in all clinical isolates tested, independent of the source of isolation, and is even 259 
capable of strongly reducing survival in multi-drug resistant strains and CF isolates.  260 
 261 
SPI009 causes no significant cytotoxicity or hemolysis 262 
The in vitro activity of SPI009 was clearly demonstrated in different experimental set-ups. An 263 
important factor determining its in vivo potential is the cytotoxicity of SPI009 in eukaryotic cell 264 
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lines. For this, embryonic kidney HEK293-T cells were treated with increasing concentrations of 265 
SPI009, ranging from 4.25 to 136 µg/mL for 24 hours. The cytotoxicity was determined by 266 
spectroscopic detection of lactate dehydrogenase with three independent repeats resulting in 267 
an IC50 value of 32.3 ± 0.81 µg/mL. Another important factor considering the clinical use of 268 
SPI009 is possible hemolytic activity. This was evaluated by exposing horse erythrocytes to 269 
increasing concentrations of SPI009 (8.5 – 34 µg/mL) during 1 hour. Absorbance was measured 270 
at 540 nm and percentage hemolysis was determined relative to the positive control (0.1 % 271 
Triton X-100). Results indicated no significant difference between the negative control or DMSO 272 
(carrier control; 0.5%) and concentrations of up to 34 µg/mL SPI009 or between the different 273 
testing agents and 0% hemolysis (Supplementary Figure S1). While the lack of any hemolytic 274 
activity is promising, additional adaptation of the chemical structure of SPI009 is desirable to 275 
further decrease the moderate cytotoxic effects without affecting its antibacterial properties 276 
when applications other than topical treatment of infections are envisioned. 277 
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Discussion 278 
The resistance of P. aeruginosa against the most commonly used antibiotics is rapidly increasing 279 
worldwide and even resistance against colistin and polymyxin B, antibiotics currently used as a 280 
last resort in the treatment of P. aeruginosa infections, has been reported (4, 36, 37). Besides 281 
this rapidly increasing multi-drug resistance, treatment of P. aeruginosa infections is further 282 
compromised by its ability to form biofilms and the presence of an antibiotic-tolerant persister 283 
fraction. Persister cells are able to withstand antibiotic treatment, thereby greatly hampering 284 
efficient eradication of the bacterial infection, contributing to the recalcitrant nature of chronic 285 
infections and increasing the chance of resistance development (13, 16, 38). Multiple 286 
international organizations and research groups acknowledge the increasing threat of bacterial 287 
infections, predicted to cause over 10 million deaths annually by 2050 (9), and research into 288 
new antibacterial and anti-persister therapies is increasing. In this study, a screen to search for 289 
novel anti-persister compounds capable of significantly decreasing the persister fraction in 290 
combination with the fluoroquinolone antibiotic ofloxacin led to the identification of 1-((2,4-291 
dichlorophenethyl)amino)-3-phenoxypropan-2-ol (SPI009).  292 
Small persister numbers, the different parallel mechanisms behind their formation and 293 
conservation and the still limited knowledge greatly impede the rational design of target-based 294 
anti-persister therapies. Nevertheless, several anti-persister molecules have been described in 295 
literature. Theoretically, there are three approaches to combat bacterial persister cells: (i) 296 
waking up persisters and thereby rendering them sensitive to an antibiotic, (ii) directly killing 297 
persister cells and (iii) preventing the formation of persister cells. Experiments on both isolated 298 
persister cells (Figure 2) and the population level (Figure 3) revealed the ability of SPI009 to 299 
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significantly decrease the number of surviving cells when added alone. These results clearly 300 
demonstrate that SPI009 does not depend on ofloxacin to exert its activity and is capable of 301 
directly killing persister cells, categorizing SPI009 in the second class of anti-persister molecules. 302 
Other examples of this class include membrane-acting molecules such as peptides shown to 303 
target Escherichia coli cells, including persisters (39), and NH125, a compound identified 304 
through large-scale screening capable of eradicating meticillin-resistant Staphylococcus aureus 305 
persisters through membrane-permeabilization (40). ADEP4, an acyldepsipeptide, promotes 306 
self-digestion in S. aureus through constitutive activation of the ClpP protease and combination 307 
with rifampicin completely eradicated biofilm infections in vitro and in vivo (32). More recently, 308 
the anti-cancer drugs mitomycin C was described to actively kill persister cells of E. coli, S. 309 
aureus and P. aeruginosa (41). A more rational approach was used in the development of the 310 
Artilysin® Art-175, consisting of a bacteriophage encoded endolysin coupled to a peptide for 311 
guidance through the bacterial outer membrane. Art-175 is capable of puncturing the 312 
peptidoglycan, resulting in cell lysis, and was shown to be active against persister cells of both P. 313 
aeruginosa (31) and Acinetobacter baumannii (42). Another target-based approach led to the 314 
identification of a group of quorum-sensing (QS) inhibitors that specifically target the P. 315 
aeruginosa MvfR system. Besides disrupting cell-to-cell communication and decreasing 316 
infection, these compounds were the first molecules identified to limit the formation of 317 
persister cells in P. aeruginosa (43). 318 
When treating a normal bacterial population, consisting of both persister and non-319 
persister cells, with SPI0009 it was observed that the activity of the compound is not restricted 320 
to non-dividing persister cells but also encompasses normal, non-persister cells (Figure 3). MIC 321 
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assays however, revealed a relatively high concentration of 150 µM for SPI009, corresponding 322 
to 51 µg/mL, well above the MIC values for most conventional anti-pseudomonal antibiotics 323 
(44). Taken together, these results suggest a primary activity against non-dividing or persister 324 
cells, with an advantageous secondary effect against normal, actively dividing cells. Coates and 325 
co-workers even suggest the use of alternative, more relevant parameters such as the minimal 326 
stationary cidal concentrations (MSC) or minimal dormicidal concentration (MDC) for the 327 
evaluation of compounds active against non-dividing cells (45–47). Experiments were further 328 
focused on stationary phase cultures since the absence of active growth, higher persister 329 
fraction and nutritional starvation result in a more pronounced antibiotic tolerance and, partly 330 
due to the similarities in biofilms, increased clinical relevance (13, 48). Other anti-persister 331 
molecules primarily aimed at targeting non-multiplying cells have been described for 332 
Mycobacterium tuberculosis (49) and S. aureus (50).  333 
While the initial screening was done in combination with ofloxacin, further experiments 334 
were undertaken to explore the combination spectrum of SPI009. The limitation of described 335 
anti-persister therapies often lies in the fact that they increase the susceptibility of persister 336 
cells to one or a limited number of antibiotics. It has however been suggested that the 337 
multidrug-tolerant persister population is actually composed of several subpopulations of 338 
persister cells, each characterized by their own tolerance profile. This hypothesis is supported 339 
by the observed differences in persister fraction upon treatment of a population with distinct 340 
classes of antibiotics (51–54). Previous results already indicated an antibiotic-independent 341 
effect and additional experiments show that SPI009 is capable of reducing the persister fraction 342 
in combination with at least two additional mechanistically different classes of antibiotics 343 
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(Figure 5). Combination of SPI009 with the commonly used aminoglycoside amikacin, which acts 344 
by inhibiting translation, or ceftazidime, a cephalosporin antibiotic acting on cell wall biogenesis, 345 
resulted in complete eradication or significant decreases in the number of surviving cells, 346 
proving that SPI009 is capable of targeting multiple subpopulations of persisters. For all 347 
antibiotics tested, the addition of SPI009 clearly enhanced bacterial killing, making it a good 348 
candidate for the case-specific design of antibacterial co-therapies. Increasing resistance to 349 
most antibiotics, together with the current lack of novel anti-pseudomonal compounds has 350 
recently increased the use of antibiotic combination therapies. Although the possible negative 351 
side-effects need to be studied in more detail, addition of a different antibiotic or non-antibiotic 352 
adjuvant to conventional therapy has the potential to lower the concentrations of both agents, 353 
reduce treatment times, combine different mode of actions and facilitate the treatment of 354 
resistant strains (55–57). 355 
The currently described anti-persister molecules can be classified in three broad 356 
categories based on their mechanism of action; (i) compounds that directly kill persister cells, (ii) 357 
compounds that sensitize persister cells for antibiotic killing and (iii) compounds that prevent or 358 
decrease persister formation. The ability of SPI009 to directly kill persister cells, combined with 359 
an excellent activity in combination with distinct classes of antibiotics suggests that SPI009 360 
belongs to this first class. Several compounds capable of directly killing persister cells have been 361 
described and include different strategies such as depolarization and destruction of the cell 362 
membrane, DNA crosslinking, inhibition of essential enzymes and generation of reactive oxygen 363 
species (20, 58, 59). Additional research will be necessary to further unravel the mode of action 364 
 o
n
 August 13, 2017 by KU Leuven University Library
http://aac.asm
.org/
D
ow
nloaded from
 
but preliminary data suggest that SPI009  acts primarily by causing membrane damage (Defraine 365 
et al., manuscript in preparation). 366 
In conclusion, we identified 1-((2,4-dichlorophenethyl)amino)-3-phenoxypropan-2-ol as a 367 
promising compound for the development of future anti-persister therapies. SPI009 is capable 368 
of significantly reducing or even eliminating the persister fraction of the Gram-negative 369 
pathogen P. aeruginosa by direct killing of antibiotic-tolerant persister cells. Due to its activity 370 
against both non-dividing and dividing cells and the possibility to combine SPI009 with 371 
mechanistically different classes of antibiotics, this molecule has the potential to serve as an 372 
adjuvant in antibacterial combination therapies to treat infections containing a mix of bacteria 373 
in different growth phases. The absence of any hemolytic effects and the limited cytotoxicity, 374 
together with the possibility to further adapt the chemical structure to increase the selectivity 375 
index, encourages further research into SPI009 and the development of novel antibacterial 376 
strategies in the fight against chronic infections. 377 
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Tables 575 
Table 1: Strains used in this study.  576 
Strain Description/ Resistance profile Source or reference  
P. aeruginosa PA14 UCBPP-PA14, wild type, KmR Pierre Cornelis 
P. aeruginosa AA249 Clinical isolate from burn wound; CipR, CfR, 
ATMR, IPMR, MEMR 
(60) 
P. aeruginosa BR642 Clinical isolate from bed pan; ATMR (60)  
P. aeruginosa BU004 Clinical isolate from throat; ATMR (60)  
P. aeruginosa BE136 Clinical isolate from bronchus; IPMR, ATMR (60)  
P. aeruginosa PA1256 Clinical isolate from CF patient Françoise van Bambeke (UCL) 
P. aeruginosa PA1255 Clinical isolate from CF patient; 
TICR, PIPR, TZPR, CAZR 
Françoise van Bambeke (UCL) 
P. aeruginosa PA272 Broncho pulmonary isolate 
PIPR, TICR 
Françoise van Bambeke (UCL) 
P. aeruginosa DAF87-
203 
Sputum isolate from CF patient 
PIPR, OFXR, CSTR 
Françoise van Bambeke (UCL) 
CIP= ciprofloxacin, CAZ= ceftazidim, ATM= aztreonam, IPM= imipenem, MEM= meropenem, PIP= 577 
piperacillin, TIC= ticarcillin, OFX= ofloxacin, CST= colistin, TZP= piperacillin-tazobactam. 578 
 579 
 580 
 581 
 582 
 583 
 584 
 585 
 586 
 587 
 588 
 589 
 590 
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Table 2: Structure- activity relationship for SPI009 and chemical analogs. 591 
 
 
Code R1 R2 R3 R4 Log (CFU /mL)1 
Fold decrease 
compared to 
ofloxacin 
P-value2 
SPI001 
 
OH H 
 
1.90 2527.1 <0.05 
SPI002 
 
OH 
 
5.53 0.6 NS 
SPI003 
 
OH  
 
5.57 0.5 NS 
SPI004 
 
OH H 
 
3.05 176.4 NS 
SPI005 
 
OH   4.95 2.2 NS 
SPI006 
 
OH  
 
5.53 0.6 NS 
SPI007 
 
OH 
  
5.14 1.4 NS 
SPI008 
 
OH  
 
4.89 2.6 NS 
SPI009 
 
OH H 
 
1.44 7198.2 <0.0005 
SPI010 
 
OH H 
 
3.71 39.2 <0.005 
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SPI011 
 
OH H 
 
4.87 2.7 NS 
SPI012 
 
OH 
 
 
4.76 3.5 NS 
SPI013 
 
OH   4.85 2.8 NS 
SPI014 
 
OH H 
 
5.08 1.6 NS 
SPI015 
 
H H 
 
1.74 3647.2 <0.0005 
SPI016 
 
OH H 
 
1.71 3913.6 <0.05 
SPI017 
 
OH CH3  5.68 0.4 NS 
SPI018 
 
OH H 
 
3.15 142.1 <0.0005 
SPI019 
 
OH   5.54 0.6 NS 
SPI020 
 
OH H 
 
5.25 1.1 NS 
DMSO 1%     5.30 1.0  
1
 Log (CFU/mL) represents the surviving bacteria after the five hour treatment of a stationary phase culture with 592 
the combination of 10 µg/mL ofloxacin and 200 µM compound. 593 
² P-value compared to DMSO control treatment. NS: no statistically significant difference (P > 0.05).594 
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Figure legends 595 
Figure 1: Timing of SPI009 addition to ofloxacin treatment does not influence activity. 596 
Stationary phase cells of a PA14 WT culture were treated for 72 hours with ofloxacin (filled 597 
circles) or the combination of ofloxacin with 68 µg/mL SPI009 (filled circles). SPI009 was added 598 
to the cultures at a) the beginning of treatment or b) 5 or c) 24 hours after the onset of 599 
treatment. During treatment the number of viable cells was determined at 24, 48 and 72 hours 600 
by means of CFU counting. Addition of the solvent DMSO (1%, v:v) did not result in any 601 
significant killing of the bacterial cells (data not shown). Data points represent the averages of 602 
three independent repeats, error bars indicate Standard Error of the Mean (SEM).  603 
 604 
Figure 2: SPI009 directly kills isolated persister cells. Persister cells were isolated by means of 605 
ofloxacin treatment, after which they were treated for 5 hours with either 1% DMSO, 10 µg/mL 606 
ofloxacin (OFX), 17 to 68 µg/mL SPI009 or the combination of ofloxacin with SPI009. After 607 
treatment, cells were washed, diluted and plated out to determine the number of surviving 608 
persister cells. Data points correspond to the mean of three independent repeats, error bars 609 
represent SEM-values. Significant differences are determined on log10-transformed data in 610 
comparison to ofloxacin treatment, unless indicated otherwise. * P ≤ 0.05, ** P ≤ 0.01, ***P ≤ 611 
0.001, **** P ≤ 0.0001. ND, not detected.  612 
 613 
Figure 3: SPI009 targets both normal and persister cells. Stationary phase cells of P. aeruginosa 614 
PA14 WT were treated for 5 hours with 1% DMSO (control), 10 µg/mL ofloxacin (OFX) or 17 to 615 
68 µg/mL of SPI009. After treatment, cells where washed, diluted and plated onto solid medium 616 
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to determine the number of surviving cells. Data points represent the mean of three 617 
independent repeats. Error bars represent SEM. Statistical analysis was performed on log-618 
transformed CFU data comparing different treatment conditions with the effect of ofloxacin 619 
treatment, where* P ≤ 0.05, ** P ≤ 0.01, ***P ≤ 0.001, **** P ≤ 0.0001. ND, not detected.  620 
 621 
Figure 4: Killing kinetics of SPI009 as a mono- or combination therapy. Stationary phase cells 622 
were treated with 1% DSMO (control, solid line); 10 µg/mL ofloxacin (OFX; filled circles); 17 or 623 
34 µg/mL SPI009 (open squares and triangles, respectively) or the combination treatment of 624 
ofloxacin with 17 or 34 µg/mL SPI009 (filled squares and triangles, respectively). Samples were 625 
taken 15’, 30’, 1 h, 2 h, 3 h, 4 h, 5 h and 24 hours after the onset of treatment after which they 626 
were washed and appropriate dilutions were plated out to assess the number of surviving cells. 627 
Data points represent the averages of at least three independent repeats with error bars 628 
indicating SEM values.  629 
Figure 5: The combination of SPI009 with antibiotic of distinct classes reveals an antibiotic-630 
independent effect. a) Stationary phase cells and b) exponential phase cells of P. aeruginosa 631 
PA14 WT were treated for 5 hours with ofloxacin (OFX, 10 µg/mL), amikacin (AMK, 75 µg/ml) or 632 
ceftazidime (CAZ, 30 µg/mL), respectively, in combination with 1% DMSO (black bars) or 17-34 633 
µg/mL SPI009 (white bars). Data points correspond to the mean of three independent repeats. 634 
Error bars represent SEM. ND, not detected. Statistical analysis compared the effect of antibiotic 635 
treatment alone with that of the different combination treatments with significance 636 
corresponding to * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001 and **** P ≤ 0.0001. ND, not detected. 637 
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Figure 6: The effect of SPI009 against several clinical P. aeruginosa isolates. a) Stationary phase 638 
cells of several clinical isolates were treated for 5 hours with ofloxacin (OFX) alone (black bars) 639 
or combined with SPI009 (white bars). After treatment, cells were washed, diluted and plated 640 
onto solid medium to determine the number of surviving cells. Data points represent the means 641 
of at least three independent repeats, error bars represent SEM. Statistical analysis was done on 642 
log10-transformed CFU data with * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. ND, 643 
not detected. b) Resistance profiles of the different strains with imipenem (IPM), meropenem 644 
(MEM), ceftazidim (CAZ), aztreonam (ATM), ciprofloxacin (CIP), piperacillin (PIP), ticarcillin (TIC), 645 
ofloxacin (OFX), colistin (CST), piperacillin-tazobactam (TZP). 646 
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Table 1: Strains used in this study.  
Strain Description/ Resistance profile Source or reference  
P. aeruginosa PA14 UCBPP-PA14, wild type, Km
R
 Pierre Cornelis 
P. aeruginosa AA249 Clinical isolate from burn wound; Cip
R
, Cf
R
, 
ATM
R
, IPM
R
, MEM
R 
(60) 
P. aeruginosa BR642 Clinical isolate from bed pan; ATM
R
 (60)  
P. aeruginosa BU004 Clinical isolate from throat; ATM
R
 (60)  
P. aeruginosa BE136 Clinical isolate from bronchus; IPM
R
, ATM
R 
(60)  
P. aeruginosa PA1256 Clinical isolate from CF patient Françoise van Bambeke (UCL) 
P. aeruginosa PA1255 Clinical isolate from CF patient; 
TIC
R
, PIP
R
, TZP
R
, CAZ
R
 
Françoise van Bambeke (UCL) 
P. aeruginosa PA272 Broncho pulmonary isolate 
PIP
R
, TIC
R
 
Françoise van Bambeke (UCL) 
P. aeruginosa DAF87-
203 
Sputum isolate from CF patient 
PIP
R
, OFX
R
, CST
R
 
Françoise van Bambeke (UCL) 
CIP= ciprofloxacin, CAZ= ceftazidim, ATM= aztreonam, IPM= imipenem, MEM= meropenem, PIP= 
piperacillin, TIC= ticarcillin, OFX= ofloxacin, CST= colistin, TZP= piperacillin-tazobactam. 
 
 o
n
 August 13, 2017 by KU Leuven University Library
http://aac.asm
.org/
D
ow
nloaded from
 
Table 2: Structure- activity relationship for SPI009 and chemical analogs. 
 
 
Code R
1 
R
2 
R
3 
R
4 
Log (CFU /mL)
1
 
Fold decrease 
compared to 
ofloxacin 
P-value
2
 
SPI001 
 
OH H 
 
1.90 2527.1 <0.05 
SPI002 
 
OH 
 
5.53 0.6 NS 
SPI003 
 
OH  
 
5.57 0.5 NS 
SPI004 
 
OH H 
 
3.05 176.4 NS 
SPI005 
 
OH   4.95 2.2 NS 
SPI006 
 
OH  
 
5.53 0.6 NS 
SPI007 
 
OH 
  
5.14 1.4 NS 
SPI008 
 
OH  
 
4.89 2.6 NS 
SPI009 
 
OH H 
 
1.44 7198.2 <0.0005 
SPI010 
 
OH H 
 
3.71 39.2 <0.005 
SPI011 
 
OH H 
 
4.87 2.7 NS 
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Code R
1 
R
2 
R
3 
R
4 
Log (CFU /mL)
1 
Fold decrease 
compared to 
ofloxacin 
P-value
2 
SPI012 
 
OH 
 
 
4.76 3.5 NS 
SPI013 
 
OH   4.85 2.8 NS 
SPI014 
 
OH H 
 
5.08 1.6 NS 
SPI015 
 
H H 
 
1.74 3647.2 <0.0005 
SPI016 
 
OH H 
 
1.71 3913.6 <0.05 
SPI017 
 
OH CH3  5.68 0.4 NS 
SPI018 
 
OH H 
 
3.15 142.1 <0.0005 
SPI019 
 
OH   5.54 0.6 NS 
SPI020 
 
OH H 
 
5.25 1.1 NS 
DMSO 1%     5.30 1.0  
1
 Log (CFU/mL) represents the surviving bacteria after the five hour treatment of a stationary phase culture with 
the combination of 10 µg/mL ofloxacin and 200 µM compound. 
2
 P-value compared to DMSO control treatment. NS: no statistically significant difference (P > 0.05). 
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